The study utilized patient-derived xenograft models to test the efficacy of GLIX1 alongside the PARP inhibitor olaparib. Results revealed that low-dose combinations outperformed both the control group and individual monotherapies. Notably, the synergistic effect produced tumor reduction comparable to cisplatin, the current standard-of-care chemotherapy.

BioLineRx Chief Executive Officer Philip Serlin noted that the trial confirms earlier in vitro observations, providing a clear path to address platinum resistance. Driven by these results, the companies intend to incorporate an ovarian cancer cohort into the expansion phase of their ongoing Phase 1/2a clinical trial. This move aims to validate whether GLIX1 can successfully sensitize HR-proficient tumors—which account for roughly half of high-grade serous ovarian cancers—to existing PARP-targeted treatments.